2
Announcements
Trials
Browse
Landscape
Status
Completed
2
Approved for marketing
2
No longer available
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Expanded_access
2
Sponsor
Conditions
Recurrence
11
Carcinoma, Non-Small-Cell Lung
11
Neoplasms
8
Prostatic Neoplasms
7
Multiple Myeloma
6
Breast Neoplasms
6
Leukemia, Myeloid, Acute
4
Small Cell Lung Carcinoma
3
Pancreatic Neoplasms
3
Lymphoma, Mantle-Cell
3
Lymphoma, Large B-Cell, Diffuse
3
Lung Neoplasms
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Lambert-Eaton Myasthenic Syndrome
3
HER2-positive Breast Cancer
3
Glioma
3
Carcinoma, Medullary
3
Thyroid Neoplasms
2
Stomach Neoplasms
2
Pheochromocytoma
2
Paraganglioma
2
Ovarian Neoplasms
2
Neuroendocrine Tumors
2
Neoplasm Metastasis
2
Myasthenic Syndromes, Congenital
2
Lymphoma
2
Liver Neoplasms
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia
2
Head and Neck Neoplasms
2
Interventions
Amifampridine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Approved for marketing
×
Myasthenic Syndromes, Congenital
×
Clear all
NCT02189720
2025-03-26
EAP-001
Catalyst Pharmaceuticals, Inc.
Approved for marketing
NCT00872950
2022-04-11
LEMS
Lahey Clinic
Approved for marketing